《大行報告》瑞銀下調康寧傑瑞製藥-B(09966.HK)目標價至12.94元 評級「買入」
瑞銀發表評級報告指,康寧傑瑞製藥-B(09966.HK)今年上半年產品收入5,360萬元人民幣,主要來自於銷售和KN035許可費收入,而上半年研發費用為2.164億元人民幣,按年跌6.7%,淨虧損收窄至1.473億元人民幣,現金流為17億元人民幣,據管理層所述,這是足夠公司營運3至4年時間。該行將其目標價由13.22元下調至12.94元,維持其評級為「買入」。
公司核心資產KN046就1L sq-非小細胞肺癌治療料2024年獲批。另KN052及JSKN003已進行臨床階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.